Back to Annual Meeting

Back to Annual Meeting

Abstract #146063

Lisa B. Currin, LCSW, Center for Smoking Cessation, Seton Health, 849 2nd Avenue, Troy, NY 12180, 518-268-6165, lcurrin@setonhealth.org

Patients in treatment for substance abuse use tobacco at an extremely high rate of anywhere from 90-100%. Patients in recovery are dying from tobacco use at a higher rate than from the patients drug of choice. The focus of this presentation is on the details of a grant project in which, through a coalition of substance abuse providers, treatment centers were assisted with policy change toward becoming 100% tobacco free facilities and provided training and technical assistance on treating tobacco dependency in the recovering population at various levels of care. Comprehensive trainings on intervening at all stages of recovery from Intake to Discharge were emphasized as well strategies for providing support to tobacco dependent staff. Education regarding use of NRT and medication was provided as well. Empahasis will be placed on the benefits of a coaltion model approach to creating system-wide change and increasing agency motivation and committment to the issue.

Learning Objectives:

• 1.Identify appropriate interventions for treating tobacco dependency in the recovering population.
• 2.List potential steps toward a tobacco free policy in substance abuse treatment facilities.
• 3.Describe a coalition model for addressing tobacco dependency in the substance abuse field.

Keywords: Tobacco, Substance Abuse Treatment

Related Web page: www.quitsolutions.org

Presenting author's disclosure statement:
Organization/institution whose products or services will be discussed: Will discuss Mayo Clinic recommendations for use of more than 1 nicotine patch for heavy smokers

Any relevant financial relationships? No
Any institutionally-contracted trials related to this submission?

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.